Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes
Reps are promoting Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes.
Tradjenta (linagliptin) is a "me too"...similar to Onglyza (saxagliptin) and Januvia (sitagliptin). These prolong incretin activity to stimulate insulin and reduce glucagon release.
Tradjenta's only real claim to fame is that it doesn't require a lower dose for patients with impaired renal function.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote